Dermata Therapeutics Stock Pattern Recognition Piercing Pattern
| DRMA Stock | USD 1.27 -0.06 -4.51% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was eleven with a total number of output elements of fifty. The function did not return any valid pattern recognition events for the selected time horizon. The Piercing pattern may indicate Dermata Therapeutics low bullish reversal trend.
Dermata Therapeutics Technical Analysis Modules
Most technical analysis of Dermata Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Dermata from various momentum indicators to cycle indicators. When you analyze Dermata charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. Market structure and macro sensitivity help explain how Dermata Therapeutics behaves across regimes. Market-sensitive characteristics amplify cycle exposure. Dermata Therapeutics has market cap of 4.25 M, ROE of -2.03%.
Methodology
Unless otherwise specified, financial data for Dermata Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Dermata (USA Stocks:DRMA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Dermata Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Dermata Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dermata Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dermata Therapeutics' short interest history, or implied volatility extrapolated from Dermata Therapeutics options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | Hedge Favorites Invested over 60 shares | |
 | Advertising Invested few shares | |
 | Investor Favorites Invested over 200 shares | |
 | Momentum Invested over 40 shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
 | Adviser Favorites Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Macroaxis Picks Invested few shares | |
 | Driverless Cars Invested over 200 shares | |
More Resources for Dermata Stock Analysis
A comprehensive view of Dermata Therapeutics starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for Dermata Therapeutics Stock. Selected reports below provide context for Dermata Stock:Dermata Therapeutics has market cap of 4.25 M, ROE of -2.03%. Review Investing Opportunities for broader portfolio context. This reflects a position in Dermata Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Before investing in Dermata Stock, review our How to Buy Dermata Therapeutics guide for key considerations.Analysis related to Dermata Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Dermata Therapeutics market price can diverge from book value, the accounting figure shown on Dermata balance sheet. Dermata Therapeutics' market capitalization is 4.25 M. A P/B ratio of 0.95 suggests Dermata Therapeutics trades near or below book value. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
It is useful to distinguish Dermata Therapeutics' value from its trading price, which are computed with different methods. For Dermata Therapeutics, key inputs include a P/B ratio of 0.95, and ROE of -2.03%. The quoted price is simply the exchange level where supply meets demand.